Sunitinib (Sutent)

Sunitinib is an oral targeted cancer drug known as a multi-kinase inhibitor. It blocks several proteins (including VEGFR, PDGFR, KIT, and FLT3) that tumors use to grow and to build new blood vessels. It is FDA-approved for advanced kidney cancer, gastrointestinal stromal tumor (GIST) after imatinib, and pancreatic neuroendocrine tumors, and has been studied but is not approved for mesothelioma.

Origin

Developed by SUGEN and Pfizer, sunitinib received FDA approval in January 2006. The "-tinib" suffix is the standard naming convention for tyrosine kinase inhibitors.

Significance in Asbestos Context

Sunitinib is not a standard treatment for mesothelioma. It has been studied in clinical trials for pleural mesothelioma that has progressed after chemotherapy, but results were modest and it is not FDA-approved for this use. A patient with mesothelioma might encounter sunitinib only through a clinical trial, off-label use, or because they have a second, unrelated cancer such as kidney cancer. For most mesothelioma patients, first-line therapy is chemotherapy (pemetrexed plus platinum) or immunotherapy (nivolumab plus ipilimumab), with targeted agents like sunitinib reserved for specific situations.

Example Sentence

"Because standard chemotherapy had stopped working, the oncologist discussed enrolling the patient in a clinical trial that included sunitinib as a second-line option for pleural mesothelioma."

Related Terms

Mesothelioma, Tyrosine Kinase Inhibitor, Targeted Therapy, Angiogenesis, Bevacizumab, Clinical Trial

Notes

• Ask your oncologist whether any targeted therapy, including sunitinib, has shown benefit for your specific mesothelioma subtype (epithelioid, sarcomatoid, or biphasic) and whether an active clinical trial is open.
• If sunitinib is offered, request the basis for its use (clinical trial, off-label, or for a separate cancer) and keep written records, as treatment history can be relevant to documenting damages in a legal claim.
• Watch for and report side effects promptly: high blood pressure, hand-foot syndrome, mouth sores, fatigue, diarrhea, thyroid changes, and bleeding; baseline blood pressure, thyroid, and cardiac function should be checked before starting.
• Preserve copies of all oncology notes, pathology reports, and treatment summaries. These documents support both ongoing medical care and any asbestos-related legal claim.